To ask the Secretary of State for Health and Social Care, what steps he is taking to identify high risk and vulnerable groups in the community to ensure a quick and effective roll-out of a covid-19 vaccine when one becomes available.
This answer is the replacement for a previous holding answer.
13 January 2021
The Government has now accepted the recommendations from the independent Medicines and Healthcare products Regulatory Agency (MHRA) to authorise three COVID-19 vaccines for use from Pfizer/BioNTech, Oxford University/AstraZeneca, and Moderna. This follows months of rigorous clinical trials and a thorough analysis of the data by experts at the MHRA who have concluded that all three vaccines met its strict standards of safety, quality, and effectiveness.
The Joint Committee on Vaccination and Immunisation (JCVI) are the independent experts who advise the Government on which vaccine/s the United Kingdom should use and provide advice on prioritisation at a population level. For the first phase, the JVCI has advised that the vaccine be given to care home residents and staff, as well as frontline health and social care workers, then to the rest of the population in order of age and clinical risk factors. Included in this are those with underlying health conditions, which put them at higher risk of serious disease and mortality.